CIRSE has developed a website (www.uterinefibroids. eu) that provides vital information to patients, professionals and the public on the symptoms and possible treatment options of uterine fibroid embolisation (UFE) as part of its commitment to raising public awareness of new health solutions that are both highly effective and less invasive than many existing therapies.
Fibroids of the uterus, also known as leiomyoma, fibromyoma or myoma, were first treated with Uterine Fibroid Embolisation (UFE) in France in 1989. Since then, the procedure has become widely available and is now routinely performed in many European countries. In parallel to the growth of UFE, there has been a steep increase in scientific research and literature dedicated to UFE as a safe and effective medical procedure. Unfortunately, the general public and many patients suffering from fibroids have not yet heard of this comparatively new treatment alternative. Indeed, many gynaecologists and referring doctors remain unaware of its advantages.
To help address this situation CIRSE has set up this website to provide accurate and up-to-date information based on the scientific evidence, internationally published recommendations and the expertise of its membership. All of the information on the site has been written and reviewed by physicians and patient education professionals including T. Kröncke (DE) A. Nicholson (UK) P. Pelage (FR) J. Reekers (NL) J. Spies (U.S.) and M. Trojanowska (PL).
Further information is available on: www.cirse.org and www.uterinefibroids.eu